Brokerages Set SAB Biotherapeutics, Inc. (NASDAQ:SABS) Target Price at $11.00

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $11.00.

Several equities analysts have issued reports on SABS shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Friday, April 10th. Zacks Research upgraded SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. HC Wainwright boosted their target price on SAB Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Rodman & Renshaw reiterated a “buy” rating and set a $13.00 target price on shares of SAB Biotherapeutics in a research report on Monday, May 11th. Finally, Citigroup started coverage on SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 target price on the stock.

SAB Biotherapeutics Stock Performance

NASDAQ SABS opened at $3.60 on Thursday. The company has a current ratio of 11.45, a quick ratio of 11.45 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $3.79 and its two-hundred day moving average is $3.86. SAB Biotherapeutics has a 12-month low of $1.60 and a 12-month high of $6.60. The stock has a market capitalization of $275.26 million, a price-to-earnings ratio of -1.71 and a beta of 0.55.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.15). Research analysts expect that SAB Biotherapeutics will post -1.19 EPS for the current year.

Institutional Investors Weigh In On SAB Biotherapeutics

Several institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. purchased a new stake in shares of SAB Biotherapeutics during the 1st quarter worth approximately $29,000. State of Wyoming purchased a new stake in shares of SAB Biotherapeutics during the 4th quarter worth approximately $34,000. ADAR1 Capital Management LLC boosted its stake in shares of SAB Biotherapeutics by 75.6% during the 4th quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock worth $99,000 after acquiring an additional 11,344 shares in the last quarter. State Street Corp purchased a new stake in shares of SAB Biotherapeutics during the 4th quarter worth approximately $49,000. Finally, Fifth Lane Capital LP purchased a new stake in shares of SAB Biotherapeutics during the 4th quarter worth approximately $56,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.